Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure (COMMANDER HF)

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2016 by Janssen Research & Development, LLC
Information provided by (Responsible Party):
Janssen Research & Development, LLC Identifier:
First received: June 12, 2013
Last updated: September 30, 2016
Last verified: September 2016
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: May 2018
  Estimated Primary Completion Date: May 2018 (Final data collection date for primary outcome measure)